Halozyme Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Halozyme Therapeutics, Inc. is a leading biopharmaceutical technology platform company that licenses its proprietary recombinant human hyaluronidase enzyme (rHuPH20) technology, known as ENHANZE, to major global pharmaceutical and biotechnology companies. The ENHANZE platform temporarily breaks down hyaluronan in the extracellular matrix, facilitating the rapid subcutaneous (SC) delivery of high-volume injectable biologics and small molecules, thereby reducing treatment burden and improving patient convenience. Halozyme has expanded its drug delivery portfolio through the acquisitions of Surf Bio and the development of its Hypercon hyperconcentration technology, which enables at-home and flexible administration of highly concentrated therapeutics.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Integrating the newly acquired Elektrofi (Hypercon) and Surf Bio hyperconcentration technologies to enable subcutaneous delivery of high-dose biologics in volumes below 2 mL.
Expected impact: Extends the company's royalty horizons and IP protection into the mid-2040s, targeting approximately $1 billion in royalty revenue within 5 years post first launch.
Expanding the reach of the core ENHANZE drug delivery technology through new licensing agreements, including applications in new modalities like Nucleic Acids and Antibody-Drug Conjugates (ADCs).
Expected impact: Secures new royalty streams starting in the 2030s and extending into the 2040s, offsetting potential legacy patent expirations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Surf Bio's hyperconcentration technology, which uses a protective polymer excipient and spray-dry approach to enable subcutaneous delivery of ultra-high concentration biologics.
Financial impact: Upfront payment of $300 million, with up to $100 million in potential future development and regulatory milestones. Contributed to the expansion of the 2026 investment budget by approximately $60 million (combined with Elektrofi).
Acquisition of Elektrofi's Hypercon technology, a breakthrough microparticle platform that enables high protein concentrations (400-500 mg/mL) for subcutaneous self-administration.
Financial impact: Upfront payment of $750 million in cash, with up to $150 million in future contingent milestone payments ($50 million each for the marketing approval of the first three Hypercon products).
Acquisition of Antares' best-in-class auto-injector platform and specialty commercial business to create a leading drug delivery and specialty product company.
Financial impact: All-cash transaction valued at approximately $960 million ($5.60 per share). Immediately accretive to Halozyme's revenue and earnings, adding commercial products like XYOSTED.
Strategic Partnerships
Provides GSK access to ENHANZE technology for multiple oncology targets, representing the first potential application of ENHANZE in antibody-drug conjugates (ADCs).
Terms: GSK will make an upfront payment, potential future milestone payments, and royalties on net sales of developed products.
Provides Vertex access to the newly acquired Hypercon technology for use in up to three targets.
Terms: Vertex will make a $15 million upfront payment, with potential future milestone payments and royalties on net sales of developed products.
Provides Oruka access to Hypercon technology for use with ORKA-001 (in development for psoriasis) and one additional target.
Terms: Oruka will make an upfront payment, potential future milestone payments, and mid-single digit royalties on net sales of developed products.